Company intelligence / Profile preview

Editpep

Berkeley, California, United Stateseditpep.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Editpep has developed a proprietary class of peptides that enable the delivery of CRISPR enzymes into clinically relevant and previously untransfectable cell types. The company’s technology aims to unlock new possibilities for gene editing therapies by overcoming major barriers in cellular delivery. No clinical results have been reported as the company appears to be preclinical/seed stage.

Therapeutic areas: Other
Modalities: PeptidesCRISPR-based gene editing
Industry: Biotech

Partnerships

Berkeley SkyDeck Fund / UC Berkeley Life Sciences Entrepreneurship Center partnership for funding and acceleration support

Beyond the preview

Go deeper on Editpep.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Editpep.

Explore the full profile